We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
Read MoreHide Full Article
Novartis (NVS - Free Report) announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway. APPULSE-PNH is a phase IIIB multicenter, single-arm, open-label study to evaluate the efficacy and safety of twice-daily oral Fabhalta monotherapy (200mg) in adults with PNH who were switched from anti-C5 therapies (eculizumab or ravulizumab).
Year to date, shares of Novartis have risen 0.7% compared with the industry’s growth of 9.5%.
Image Source: Zacks Investment Research
More on NVS’ Study of Fabhalta
The APPULSE-PNH study enrolled 52 participants who received Fabhalta for 24 weeks.
In the Phase IIIB APPULSE-PNH study, oral Fabhalta improved the average hemoglobin (Hb) level versus baseline in adult patients with PNH who were switched from anti-C5 therapies.
The positive results reinforce Fabhalta's ability to benefit both patients previously treated with anti-C5 therapies studied in the APPULSE-PNH and APPLY-PNH trials and complement-inhibitor naïve patients studied in the APPOINT-PNH trial.
The safety profile of Fabhalta monotherapy was consistent with previously reported data.
Fabhalta obtained FDA approval in December 2023 for the treatment of adults with PNH. It also received the European Medicines Agency’s approval in May 2024 for the treatment of adults with PNH with hemolytic anemia.
We remind investors that the FDA recently granted Fabhalta accelerated approval for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Fabhalta is being evaluated in a broad range of rare kidney diseases, including C3 glomerulopathy, atypical hemolytic uremic syndrome, immune complex membranoproliferative glomerulonephritis and lupus nephritis.
NVS Presents Long-Term Data on Scemblix
Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib).
Scemblix demonstrated sustained superior major molecular response (MMR) versus all investigator-selected tyrosine kinase inhibitors (TKIs) and versus imatinib alone. Scemblix met both key secondary endpoints at the end of 96 weeks.
Scemblix showed a clinically relevant 15.1% higher MMR rate versus second-generation TKIs (72.0% versus 56.9%).
NVS Looks to Strengthen Pipeline
NVS is a pure-play innovative medicine company with a focus on core therapeutic areas — cardiovascular, renal and metabolic, immunology, neuroscience and oncology.
Novartis’ performance in the third quarter was impressive, with both earnings and sales beating estimates. The increase in annual guidance was another positive, indicating strong momentum across all key drugs in the upcoming quarters.
Novartis recently increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with the previous estimate of 5%.
The rise in guidance was due to the strong momentum of NVS’ key drugs and its upcoming launches.
While organic growth continues to drive business, NVS is focused on strategic bolt-in acquisitions to strengthen its pipeline.
Novartis recently entered into a global license and collaboration agreement with PTC Therapeutics (PTCT - Free Report) for the latter’s Huntington's disease candidate to strengthen NVS’ neuroscience pipeline.
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in development, regulatory and sales milestones. NVS will also share profits in the United States (40% PTC and 60% Novartis) and pay tiered royalties on ex-US sales.
NVS announced a collaboration with Olema Pharmaceuticals, Inc. (OLMA - Free Report) for a breast cancer drug.
Per the terms of the deal, Novartis will provide Olema with its breast cancer drug Kisqali (ribociclib) for the planned phase III OPERA-02 trial of Olema’s palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer.
NVS’ Zacks Rank & Stock to Consider
Novartis currently carries a Zacks Rank #3 (Hold).
Over the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.84 to $2.91. PFE’s shares have lost 10% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
Novartis (NVS - Free Report) announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway.
APPULSE-PNH is a phase IIIB multicenter, single-arm, open-label study to evaluate the efficacy and safety of twice-daily oral Fabhalta monotherapy (200mg) in adults with PNH who were switched from anti-C5 therapies (eculizumab or ravulizumab).
Year to date, shares of Novartis have risen 0.7% compared with the industry’s growth of 9.5%.
Image Source: Zacks Investment Research
More on NVS’ Study of Fabhalta
The APPULSE-PNH study enrolled 52 participants who received Fabhalta for 24 weeks.
In the Phase IIIB APPULSE-PNH study, oral Fabhalta improved the average hemoglobin (Hb) level versus baseline in adult patients with PNH who were switched from anti-C5 therapies.
The positive results reinforce Fabhalta's ability to benefit both patients previously treated with anti-C5 therapies studied in the APPULSE-PNH and APPLY-PNH trials and complement-inhibitor naïve patients studied in the APPOINT-PNH trial.
The safety profile of Fabhalta monotherapy was consistent with previously reported data.
Fabhalta obtained FDA approval in December 2023 for the treatment of adults with PNH. It also received the European Medicines Agency’s approval in May 2024 for the treatment of adults with PNH with hemolytic anemia.
We remind investors that the FDA recently granted Fabhalta accelerated approval for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Fabhalta is being evaluated in a broad range of rare kidney diseases, including C3 glomerulopathy, atypical hemolytic uremic syndrome, immune complex membranoproliferative glomerulonephritis and lupus nephritis.
NVS Presents Long-Term Data on Scemblix
Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib).
Scemblix demonstrated sustained superior major molecular response (MMR) versus all investigator-selected tyrosine kinase inhibitors (TKIs) and versus imatinib alone. Scemblix met both key secondary endpoints at the end of 96 weeks.
Scemblix showed a clinically relevant 15.1% higher MMR rate versus second-generation TKIs (72.0% versus 56.9%).
NVS Looks to Strengthen Pipeline
NVS is a pure-play innovative medicine company with a focus on core therapeutic areas — cardiovascular, renal and metabolic, immunology, neuroscience and oncology.
Novartis’ performance in the third quarter was impressive, with both earnings and sales beating estimates. The increase in annual guidance was another positive, indicating strong momentum across all key drugs in the upcoming quarters.
Novartis recently increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with the previous estimate of 5%.
The rise in guidance was due to the strong momentum of NVS’ key drugs and its upcoming launches.
While organic growth continues to drive business, NVS is focused on strategic bolt-in acquisitions to strengthen its pipeline.
Novartis recently entered into a global license and collaboration agreement with PTC Therapeutics (PTCT - Free Report) for the latter’s Huntington's disease candidate to strengthen NVS’ neuroscience pipeline.
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in development, regulatory and sales milestones. NVS will also share profits in the United States (40% PTC and 60% Novartis) and pay tiered royalties on ex-US sales.
NVS announced a collaboration with Olema Pharmaceuticals, Inc. (OLMA - Free Report) for a breast cancer drug.
Per the terms of the deal, Novartis will provide Olema with its breast cancer drug Kisqali (ribociclib) for the planned phase III OPERA-02 trial of Olema’s palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer.
NVS’ Zacks Rank & Stock to Consider
Novartis currently carries a Zacks Rank #3 (Hold).
A better-ranked stock from the large-cap pharma industry is Pfizer (PFE - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.84 to $2.91. PFE’s shares have lost 10% year to date.
Pfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.